linjc16/ctgov huggingface dataset:
Factors Influencing Perioperative Mortality in Type A Acute Aortic Dissections Operated at Dijon University Hospital

Study Overview
=================
Brief Summary
-----------------
Type A acute aortic dissections are a rare condition whose natural evolution is catastrophic. Global mortality remains high even if it decreased last years. This is probably due to improvement of diagnostic techniques and the evolution of surgical practices. It is however important to have medical data and statistics obtained in past years in order to better understand the factors influencing peroperative mortality and thereby to continue this improvement.

Official Title
-----------------
Factors Influencing Perioperative Mortality in Type A Acute Aortic Dissections Operated at Dijon University Hospital

Conditions
-----------------
Aortic Dissection

Intervention / Treatment
-----------------
* Procedure: Acute aortic dissection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent aortic dissection surgery in Dijon Burgundy University Hospital Exclusion Criteria: patients who died before the surgical incision

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type A aortic dissection<br>Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital | Procedure: Acute aortic dissection<br>* Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Monitor peri-operative mortality incidence rates | Mortality during peri-operative acute aortic dissection procedure | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Monitor peri-operative morbidity incidence rates | Stroke, Kidney failure, Reexploration for bleeding | 1 day |
Comparison of the Efficacy of Intraocular Lens Optic Capture and In-the-bag Implantation Over 1 Year in Children With Congenital Cataract

Study Overview
=================
Brief Summary
-----------------
Approximately 30 eyes with congenital cataract who underwent primary or secondary intraocular lens implantation surgery at Zhejiang Eye Hospital from March 2018 to December 2020 were enrolled. According to the implantation method of IOL, patients were devided into the optic capture group and the endocapsular group. And through the clinical parameters of postoperative best corrected visual acuity (BCVA), intraocular pressure (IOP), IOL position and whether appear visual axis opacity to compare the outcome of the 2 IOL implantation methods.

Official Title
-----------------
Comparison of the Efficacy of Intraocular Lens Optic Capture and In-the-bag Implantation Over 1 Year in Children With Congenital Cataract

Conditions
-----------------
Congenital Cataract, Intraocular Lens Implantation, Optic Capture

Intervention / Treatment
-----------------
* Procedure: primary or secondary intraocular lens implantation surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 1 to 10 years diagnosed with congenital cataract underwent I / II IOL implantation in our hospital corneal diameter more than 9mm Good compliance Exclusion Criteria: Patients with other ocular or systemic diseases patients whose IOL cannot be implanted in or after the capsule due to ocular conditions Children with a history of other ocular surgery Low compliance

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| optic capture group<br>IOL optic was captured through the posterior continuous curvilinear capsulorhexis | Procedure: primary or secondary intraocular lens implantation surgery<br>* primary or secondary intraocular lens implantation surgery<br>|
| endocapsular group<br>IOL was placed in the bag | Procedure: primary or secondary intraocular lens implantation surgery<br>* primary or secondary intraocular lens implantation surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOL position | The horizontal and vertical inclination of IOL | through study completion, an average of 1 year | 
| BCVA | best corrected visual acuity | through study completion, an average of 1 year |
Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling

Study Overview
=================
Brief Summary
-----------------
The hypothesis is men with stress urinary incontinence, including those following radical retropubic prostatectomy and other prostate surgery, have preoperative urethral mobility as measured by magnetic resonance imaging (MRI) that improves significantly following sling placement. The investigators theorize that the sling helps with primary hypermobility of this pathophysiologic cause of stress urinary incontinence.

Official Title
-----------------
Prospective Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling

Conditions
-----------------
Male Stress Urinary Incontinence

Intervention / Treatment
-----------------
* Other: Pre and Post Sling Pelvic MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The control group: normal male subjects The Intervention group: male with stress urinary incontinence 45 years or older history of prior radical prostatectomy complains of stress urinary incontinence scheduled for a transobturator sling surgery ability and willingness to provide written consent Exclusion Criteria: absolute or relative contraindications to MRI claustrophobia inability to undergo the male sling surgery PI judgement Absolute contraindications to MRI: electronically, magnetically, and mechanically activated implants ferromagnetic or electronically operated active devices metallic splinters in the eye ferromagnetic hemostatic clips in the central nervous system Relative contraindications to MRI: cochlear implants other pacemakers nerve stimulators lead wires or similar wires prosthetic heart valves hemostatic clips non-ferromagnetic stapedial implants

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pre and Post Sling Pelvic MRI<br>Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI. | Other: Pre and Post Sling Pelvic MRI<br>* Pre and Post Sling Pelvic MRI<br>* Other names: Transobturator suspension sling system (TOS), AMS Advance;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in urethral mobility | Measure change in urethral mobility from baseline versus 2-5 months post-surgery versus no surgical intervention. | Within 2-5 months after enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stress urinary incontinence, male, transobturator sling, SUI
Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.

Study Overview
=================
Brief Summary
-----------------
This study is being done to see if there are any long term health related issues in women with APA and recurrent miscarriages.

Detailed Description
-----------------
The association between APA and thrombosis is well documented. Both LA and ACA are often detected in individuals with SLE but there is no prospective data on the risk of thrombosis in women who present with recurrent miscarriages in association with APA. This study should significantly advance medical knowledge of the natural history of primary antiphospholipid syndrome (PAPS) which is essential to enable optimal management of relatively young women who may be at risk of complications, some of which are potentially life threatening.

Official Title
-----------------
Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies in Women Presenting as Recurrent Miscarriages.

Conditions
-----------------
Antiphospholipid Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Antiphospholipid syndrome History of recurrent miscarriages Exclusion Criteria: Previous thromboembolic disease
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antiphospholipid syndrome
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Study Overview
=================
Brief Summary
-----------------
This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Official Title
-----------------
An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Conditions
-----------------
Attention Deficit Disorder

Intervention / Treatment
-----------------
* Drug: Extended-release bupropion hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patient must be diagnosed with ADHD. Exclusion Criteria: Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia. Patient has a current diagnosis of Major Depressive Disorder (MDD). Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months. Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders. Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Extended-release bupropion hydrochloride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADHD Rating Scale |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Global Impressions -Severity and Improvement. |  |  | 
| Quality of Life Enjoyment and Satisfaction Questionnaire. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ADD, ADHD, attention deficit, hyperactivity
HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection

Study Overview
=================
Brief Summary
-----------------
The trial will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy treatment regimens.

Detailed Description
-----------------
Longitudinal study of circulating and intra-hepatic HBV-specific T-cell immunity in the setting of a randomised, controlled, international, multi-centre outpatient trial. The trial will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy treatment regimens. Study population: Patients with HIV/HBV co-infection who are naive to HIV/HBV therapy, have detectable HBV viremia and are willing to start antiretroviral therapy.

Official Title
-----------------
Generation of HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection Receiving HBV-active Antiretroviral Therapy

Conditions
-----------------
HIV, Hepatitis-B

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV positive hepatitis-B co-infected HBV/HIV therapy naive >18 years of age Exclusion Criteria: Unable to sign consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize circulating and intra-hepatic anti-HBV T-cell responses longitudinally in HIV-1/HBV co-infected individuals, following effective anti-HBV therapy |  | 48 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To identify novel CD4 and CD8 T cell HBV epitopes associated with HBV clearance. |  | 48 weeks | 
| To identify emergence of cytotoxic T lymphocyte (CTL) escape mutants following anti-HBV therapy |  | 48 weeks | 
| To determine the effect of HIV-1 co-infection and anti-HBV T-cell responses on clearance of free virions and HBV reservoirs using viral dynamic parameters and direct quantification of HBV hepatic reservoirs |  | 48 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV infection, Hepatitis coinfection
Arthrocentesis Followed by Prolotherapy

Study Overview
=================
Brief Summary
-----------------
we will do tmj joint lavage and followed by dextrose injection

Detailed Description
-----------------
Two groups of patients one group will receive lavage with saline and other group will receive lavage then dextrose injection

Official Title
-----------------
TMJ Lavage Followed by Dextrose Prolotherapy

Conditions
-----------------
TMJ Pain

Intervention / Treatment
-----------------
* Other: joint lavage with dextrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: tmj painful joints patients healthy patients disk displacement with reduction Exclusion Criteria: patients previously treated males young age group

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group 1<br>lavage by dextrose | Other: joint lavage with dextrose<br>* joint lavage with dextrose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain scores | Change in pain symptoms measured by visual analogue scale 1=better-to-10 worse | 3 months | 
| Maximum mouth opening measured in millimeter 36mm=normal, less than 36mm=worse | Change in mouth opening- decrease =worse | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain symptoms measured by visual analogue scale | Measurement of change in pain scores from 1-10, 1=better-to-10 worse | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tmj, pain
Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea syndrome (OSA) is a disease affecting 5-15% of population and 50-80% of type 2 diabetes mellitus (T2DM) and obese subjects. OSA causally contributes to the development of glucose intolerance and T2DM. The project is targeting the gap in providing effective treatment of metabolic impairments associated with OSA, particularly T2DM. In contrast to proved benefits of OSA treatment with CPAP (continuous positive airway pressure) on cardiovascular morbidity/mortality, studies on the impact of CPAP on diabetes control are disappointing. In fact, OSA-induced metabolic impairments might not be reversible with CPAP treatment, as investigators suggested recently. Clearly, the search for additional treatments, probably pharmacological, is warranted. Investigators hypothesize that elevated levels of free fatty acids (FFA), as detected in OSA patients, are linking OSA with the T2DM development. The aim of the study is to target adipose tissue and muscle dysfunction leading to elevated FFA and develop thus novel pharmacological treatments based on lipolysis inhibition and stimulation of FFA oxidation.

Official Title
-----------------
Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)

Conditions
-----------------
Obstructive Sleep Apnea, Fatty Acid Metabolism, Continuous Positive Airway Pressure

Intervention / Treatment
-----------------
* Device: CPAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes mellitus Age 18 - 85 years BMI 22-40 kg/m2 moderate or severe OSA diagnosed by home sleep study Exclusion Criteria: treatment with insulin other acute or chronic endocrine or inflammatory disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OSA + T2DM<br>CPAP treatment | Device: CPAP<br>* Continuous Positive Airway Pressure in cases of moderate/severe OSA<br>|
| Experimental: OSA no T2DM<br>CPAP treatment | Device: CPAP<br>* Continuous Positive Airway Pressure in cases of moderate/severe OSA<br>|
| No Intervention: T2DM no OSA<br>Standard care | |
| No Intervention: Healthy controls no ÓSA<br>no intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycerol release (lipolysis) in adipose tissue | Changes in interstitial glycerol concentration in adipose tissue | Baseline and 6 months | 
| Palmitate oxidation in skeletal muscle | Changes in palmitate oxidation in muscle biopsies measured ex vivo | Baseline and 6 months |
Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Epiretinal Membrane

Study Overview
=================
Brief Summary
-----------------
Purpose: To evaluate macular sensitivity and its correlation with visual acuity and Spectral Domain Optical Coherence Tomography (SD-OCT) in eyes with idiopathic epiretinal membrane (ERM). Design: Cross sectional case-control series. Methods: Setting: Dijon University Hospital. Patients: Forty nine patients (49 eyes) with idiopathic ERM and twenty-seven healthy patients (27 eyes) as a control group. Main outcome measurement: Microperimetry, Spectral Domain Optical Coherence Tomography (SD-OCT).

Official Title
-----------------
Retinal Sensitivity and Optical Coherence Tomography Findings in Eyes With Idiopathic Epiretinal Membrane

Conditions
-----------------
Epiretinal Membrane

Intervention / Treatment
-----------------
* Procedure: Epiretinal Membrane Surgical treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Epiretinal Membrane Exclusion Criteria: Age related macular degeneration Diabetic macular edema

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Epiretinal Membrane<br>The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned. | Procedure: Epiretinal Membrane Surgical treatment<br>* epiretinal membrane peeling<br>|
| No Intervention: Control<br>Subjects with normal visual acuity and OCT profile | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macular sensitivity | The objective of this study was to assess macular function by measuring its sensitivity using microperimetry in patients with idiopathic ERM every three months up to one year. We compared the results of macular sensitivity to the best-corrected visual acuity (BCVA) and the OCT data to better understand the structure-function relationship. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Microperimetry, OCT, idiopathic epiretinal membrane